Preeclampsia: Pathogenesis, Prevention, and Long-Term Complications

Semin Nephrol. 2017 Jul;37(4):386-397. doi: 10.1016/j.semnephrol.2017.05.011.

Abstract

Preeclampsia continues to afflict 5% to 8% of all pregnancies throughout the world and is associated with significant morbidity and mortality to the mother and the fetus. Although the pathogenesis of the disorder has not yet been fully elucidated, current evidence suggests that imbalance in angiogenic factors is responsible for the clinical manifestations of the disorder, and may explain why certain populations are risk. In this review, we begin by demonstrating the roles that angiogenic factors play in pathogenesis of preeclampsia and its complications in the mother and the fetus. We then continue to report on the use of angiogenic markers as biomarkers to predict and risk-stratify disease. Strategies to treat preeclampsia by correcting the angiogenic balance, either by promoting proangiogenic factors or by removing antiangiogenic factors in both animal and human studies, are discussed. We end the review by summarizing status of the current preventive strategies and the long-term cardiovascular outcomes of women afflicted with preeclampsia.

Keywords: Antiangiogenic factors; cardiovascular complications; hypertension; preeclampsia; pregnancy.

Publication types

  • Review

MeSH terms

  • Biomarkers / blood
  • Bronchopulmonary Dysplasia / etiology
  • Cardiovascular Diseases / etiology
  • Eclampsia / therapy
  • Endoglin / blood
  • Endoglin / metabolism*
  • Female
  • Humans
  • Infant, Newborn
  • Kidney Diseases / etiology*
  • Metabolic Diseases / etiology
  • Placenta Growth Factor / blood
  • Placenta Growth Factor / metabolism*
  • Pre-Eclampsia / epidemiology
  • Pre-Eclampsia / metabolism*
  • Pre-Eclampsia / prevention & control*
  • Pre-Eclampsia / therapy
  • Pregnancy
  • Vascular Endothelial Growth Factor A / metabolism
  • Vascular Endothelial Growth Factor Receptor-1 / blood
  • Vascular Endothelial Growth Factor Receptor-1 / metabolism*

Substances

  • Biomarkers
  • ENG protein, human
  • Endoglin
  • Vascular Endothelial Growth Factor A
  • Placenta Growth Factor
  • FLT1 protein, human
  • Vascular Endothelial Growth Factor Receptor-1